SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

Phase 3TerminatedNCT00440271

Boehringer Ingelheim33 enrolled

Overview

The primary purpose of this study is to: 1. Demonstrate the safety and efficacy of tipranavir/ritonavir (TPV/r) among a racially diverse HIV+ population (males and females) who are three-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI)) experienced with documented resistance to more than one PI. 2. Determine pharmacokinetic data in this racially and gender diverse population. 3. Determine the potential utility of using therapeutic drug monitoring (TDM) in improving efficacy outcomes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

HIV Infections

Interventions

tipranavir

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Main inclusion criteria for the study are: 1. HIV-1 infected adults, men and women at least 18 years of age. 2. 3-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI)) treatment-experienced (min of 3-months duration for each class) with resistance to more than one PI (on screening resistance testing). NNRTI-naïve patients who have genotypically documented NNRTI-resistance mutations on past or screening resistance testing would be eligible. 3. CD4+ T lymphocyte count \>=50 cells/mm3. 4. HIV-1 viral load \>=1,000 copies/mL at screening. 5. The antiretroviral (ARV) study treatment regimen must consist of TPV/r in combo with an optimized background regimen (OBR) of 2-4 agents: N(t)RTIs (NRTI or NtRTI), enfuvirtide (ENF), and/or, where available, a trial approved expanded access program (EAP) investigational agent. 6. Acceptable screening laboratory values that indicate adequate baseline organ function. 7. Acceptable medical history with a chest X-ray without evidence of active disease and an electrocardiogram (ECG) without clinically important abnormalities within one year of the study. 8. A reliable method of barrier contraception will be used by all female patients who are of childbearing potential. Exclusion Criteria: Main exclusion criteria for the study are: 1. Known hypersensitivity to the tipranavir (TPV) or ritonavir (RTV). 2. ARV medication naïve. 3. Genotypic resistance to TPV (defined as a TPV mutation score \>7). 4. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for at least 7 consecutive days within the month prior to screening. 5. Prior tipranavir use. 6. Inability to adhere to the requirements of the protocol. 7. Patients with prior history of hemorrhagic stroke or intracranial aneurysm. 8. Patients with a history of ischemic stroke, neurosurgery or skull trauma within 4 weeks prior to screening. 9. History of Progressive Multifocal Leukoencephalopathy, Visceral Kaposi's Sarcoma, and/or any malignancy. 10. Any acquired immunodeficiency syndrome (AIDS) defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit.

Locations (30)

1182.98.033 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

1182.98.018 Boehringer Ingelheim Investigational Site

Clearwater, Florida, United States

1182.98.014 Boehringer Ingelheim Investigational Site

Fort Lauderdale, Florida, United States

1182.98.041 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

1182.98.004 Boehringer Ingelheim Investigational Site

Decatur, Georgia, United States

Outcomes

Primary Outcomes

Treatment Response at Week 48

percentage of participants whose viral load \<50 copies/mL at Week 48

Time frame: after 48 weeks of treatment

Secondary Outcomes

Percentage of Participants Whose Viral Load <50 Copies/mL at Each Visit Including Visits at Weeks 24 and 48

Time frame: after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)

Percentage of Participants Whose Viral Load <400 Copies/mL at Each Visit Including Visits at Weeks 24 and 48

Time frame: after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)

Percentage of Participants Whose ≥1 log10 Drop in Viral Load From Baseline at All Visits, Including Visits at Weeks 24 and 48

Time frame: after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)

Change in Viral Load From Baseline at Each Visit

Time frame: after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)

Time to Treatment Failure

For patients who never achieve a confirmed virologic response, time to treatment failure is defined as 0. For patients who achieve a confirmed virologic response, time to treatment failure is the earliest time of either: death, permanent discontinuation of the study drug or loss to follow-up, introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background drug, but not the study drug, or first occurrence of a VL \>50 copies/mL at two consecutive measurements after having achieved a VL \<50 copies/mL.

Time frame: after Day 1 of treatment

Time to New AIDS or AIDS Related Progression Event or Death

Time frame: after Day 1 of treatment

Change in CD4+ and CD8+ Cell Counts From Baseline at Each Visit Including Visits at Week 24 and Week 48

Time frame: after 2 weeks of treatment till Week 48 (Weeks 2, 4, 8, 12, 24, 36, and 48)

Change in Ratio of CD38+/CD8+ From Baseline to Week 48

Time frame: after 2 weeks of treatment till Week 48 (Weeks 2, 4, 8, 12, 24, 36, and 48)

Tipranavir (TPV) and Ritonavir (RTV) Trough Concentrations at Week 2, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48

Time frame: after 2 weeks of treatment till Week 48 (Weeks 2, 4, 8, 12, 24, 36, and 48)

Patients Adherence With Study Medication Based on Pill Count

Time frame: after 4 weeks of treatment

Occurrence of TPV Inhibitory Quotient (IQ) >60 at Each Visit Where TPV Concentration is Measured

Time frame: after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)

Occurrence of TPV Trough Concentration >120 μM

Time frame: after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)

Post-dose TPV and RTV Concentrations at Week 4

Time frame: Week 4